- Home
- HOLX vs MRNA Comparison
HOLX vs MRNA Comparison
Compare HOLX & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLX
- MRNA
- Stock Information
- Founded
- HOLX 1985
- MRNA 2010
- Country
- HOLX United States
- MRNA United States
- Employees
- HOLX N/A
- MRNA N/A
- Industry
- HOLX Medical Electronics
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOLX Health Care
- MRNA Health Care
- Exchange
- HOLX Nasdaq
- MRNA Nasdaq
- Market Cap
- HOLX 16.7B
- MRNA 16.0B
- IPO Year
- HOLX 1990
- MRNA 2018
- Fundamental
- Price
- HOLX $69.73
- MRNA $34.06
- Analyst Decision
- HOLX Buy
- MRNA Hold
- Analyst Count
- HOLX 14
- MRNA 20
- Target Price
- HOLX $88.92
- MRNA $76.35
- AVG Volume (30 Days)
- HOLX 2.7M
- MRNA 10.7M
- Earning Date
- HOLX 02-05-2025
- MRNA 02-20-2025
- Dividend Yield
- HOLX N/A
- MRNA N/A
- EPS Growth
- HOLX 81.42
- MRNA N/A
- EPS
- HOLX 3.32
- MRNA N/A
- Revenue
- HOLX $4,030,300,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- HOLX $5.40
- MRNA N/A
- Revenue Next Year
- HOLX $5.74
- MRNA N/A
- P/E Ratio
- HOLX $21.00
- MRNA N/A
- Revenue Growth
- HOLX N/A
- MRNA N/A
- 52 Week Low
- HOLX $68.61
- MRNA $31.94
- 52 Week High
- HOLX $84.67
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- HOLX 34.61
- MRNA 34.88
- Support Level
- HOLX $68.61
- MRNA $33.34
- Resistance Level
- HOLX $72.99
- MRNA $35.68
- Average True Range (ATR)
- HOLX 1.52
- MRNA 2.46
- MACD
- HOLX -0.09
- MRNA -0.75
- Stochastic Oscillator
- HOLX 19.02
- MRNA 12.49
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.